Clinical trials and observational studies of coronary stenting have demonstrated improvement in clinical outcomes with newer-generation drug-eluting stents (DES) versus earlier-generation DES or bare-metal stents. Much of this improvement has been due to a decrease in very late events (beyond 1 year), with reductions in both target lesion revascularization (TLR) and stent thrombosis. Improved healing related to thinner stent struts and improved polymer technology is regarded as an important contributor. Despite the improved very late outcomes, events do continue to accrue, with several reports indicating ongoing TLR rates exceeding 1% per year and very late stent thrombosis approximately 0.1% per year. Additional efforts to reduce inflammation and promote vessel healing using bioresorbable scaffolds or bioresorbable polymers have not shown superiority over current durable-polymer devices, raising concern that some continued risk of these adverse very late outcomes may be inevitable.